AccScience Publishing / JCTR / Online First / DOI: 10.36922/JCTR026090015
Submit to JCTR
Cite this article
2
Download
86
Views
Related Info Links
Google Scholar
More by Authors Links
Xiuping Bai
Journal Browser
Volume | Year
Issue
Search
Forthcoming Issue
Current Issue
View All
News and Announcements
View All
ORIGINAL ARTICLE

Influence of ursodeoxycholic acid on hepatic lipid deposition, blood glucose, and insulin levels in high-fat -fed Sprague–Dawley rats

Xiuping Bai1* ,  Yufeng Han1 ,  Lingyan Wei1 ,  Xiaojin Han1 ,  Feng Dong2
Show Less
1 Endocrinology Division, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi , China
2 Department of Radiation Oncology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas , United States of America
JCTR, 026090015 https://doi.org/10.36922/JCTR026090015
Received: 24 February 2026 | Revised: 24 July 2026 | Accepted: 18 August 2026 | Published online: 8 September 2026
© 2026 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC-by the license) ( https://creativecommons.org/licenses/by-nc/4.0/ )
Download PDF
XML
Cite
Abstract

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is becoming a growing public health concern. MASLD often coexists with abnormal glucose metabolism. Currently, there is no standard treatment for MASLD. Aim: To elucidate the influence of ursodeoxycholic acid (UDCA) on hepatic lipid deposition, blood glucose, and insulin levels in high-fat diet-induced Sprague–Dawley (SD) rats. Methods: SD rats were randomly assigned to three groups: Group A, which comprised a normal-diet control group; Group B, which comprised a high-fat-fed group; and Group C, which comprised rats treated with UDCA combined with a high-fat diet. At the end of week 4, we performed oral glucose tolerance tests, measured liver enzymes, triglyceride (TG) and total cholesterol (TC) contents, identified morphological changes of the liver, and quantified the expression of major genes in fatty acid, glucose, and bile acid metabolic pathways using real-time polymerase chain reaction. Results: In comparison to Group A, Group B had higher postprandial glucose, insulin, C-peptide, and hepatic TG and TC concentrations (all p < 0.05); metabolism-related genes were differentially expressed in Group B. In comparison to Group B, the values of these indices were all decreased in Group C (all p < 0.05); UDCA reversed the mRNA expression of metabolism-related genes in Group C (all p < 0.05). Conclusion: UDCA administration decreased hepatic lipid content, blood glucose, and insulin levels in SD rats. Relevance for patients: UDCA may be helpful in the treatment of MASLD and its related comorbidities in clinical practice.

Graphical abstract
Keywords
Ursodeoxycholic acid
Metabolic dysfunction-associated steatotic liver disease
Glucose
Insulin
Gene expression
Funding
This study was supported by international Science and Technology Cooperation and Exchange Program from the Shanxi Science and Technology Department in China (202204041101008), ShanXi Science and Technology Department of China (201901D111378 and 2014011044-3), Department of Resource and Social Security of Shanxi Province in China (2016–97), ShanXi Scholarship Council of China (2014–078), Merck Diabetes Research Program of Chinese Medical Association (13061040489).
Conflict of interest
The authors declare they have no competing interests.
References
  1. Huby T, Gautier EL. Immune cell-mediated features of non-alcoholic steatohepatitis. Nat Rev Immunol. 2022;22(7):429-443. doi: 10.1038/s41577-021-00639-3
  2. Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851-861. doi: 10.1016/S2468-1253(22)00165-0
  3. Eslam M, Sanyal AJ, George J. International Consensus Panel MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999-2014.e1. doi: 10.1053/j.gastro.2019.11.312
  4. Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908-922. doi: 10.1038/s41591-018-0104-9
  5. Ter Horst KW, Serlie MJ. Fructose Consumption, Lipogenesis, and Non-Alcoholic Fatty Liver Disease. Nutrients. 2017;9(9):981. doi: 10.3390/nu9090981
  6. Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci. 2018;75(18):3313-3327. doi: 10.1007/s00018-018-2860-6
  7. Dorn C, Riener MO, Kirovski G, et al. Expression of fatty acid synthase in nonalcoholic fatty liver disease. Int J Clin Exp Pathol. 2010;3(5):505-514.
  8. Ishii S, Iizuka K, Miller BC, Uyeda K. Carbohydrate response element binding protein directly promotes lipogenic enzyme gene transcription. Proc Natl Acad Sci USA. 2004;101(44):15597-15602. doi: 10.1073/pnas.0405238101
  9. Schlaepfer IR, Joshi M. CPT1A-mediated Fat Oxidation, Mechanisms, and Therapeutic Potential. Endocrinology. 2020;161(2):bqz046. doi: 10.1210/endocr/bqz046
  10. Alshawsh MA, Alsalahi A, Alshehade SA, et al. A Comparison of the Gene Expression Profiles of Non-Alcoholic Fatty Liver Disease between Animal Models of a High-Fat Diet and Methionine-Choline-Deficient Diet. Molecules. 2022;27(3):858. doi: 10.3390/molecules27030858
  11. Chiang JY. Bile acid metabolism and signaling. Compr Physiol. 2013;3(3):1191-1212. doi: 10.1002/j.2040-4603.2013.tb00517.x
  12. Di Ciaula A, Garruti G, Lunardi Baccetto R, et al. Bile Acid Physiology. Ann Hepatol. 2017;16:s4-s14. doi: 10.5604/01.3001.0010.5493
  13. Gottlieb A, Canbay A. Why Bile Acids Are So Important in Non-Alcoholic Fatty Liver Disease (NAFLD) Progression. Cells. 2019;8(11):1358. doi: 10.3390/cells8111358
  14. Younossi ZM, Loomba R, Anstee QM, et al. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology. 2018;68(1):349-360. doi: 10.1002/hep.29721
  15. Subudhi S, Drescher HK, Dichtel LE, et al. Distinct Hepatic Gene-Expression Patterns of NAFLD in Patients With Obesity. Hepatol Commun. 2022;6(1):77-89. doi: 10.1002/hep4.1789
  16. Ishizaki K, Imada T, Tsurufuji M. Hepatoprotective bile acid ‘ursodeoxycholic acid (UDCA)’ Property and difference as bile acids. Hepatol Res. 2005;33(2):174-177. doi: 10.1016/j.hepres.2005.09.029
  17. Beuers U. Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol. 2006;3(6):318-328. doi: 10.1038/ncpgasthep0521
  18. Bai XP, Du WJ, Xing HB, Yang GH, Bai R. Influence of ursodeoxycholic acid on blood glucose, insulin and GLP-1 in rats with liver fibrosis induced by bile duct ligation. Diabetol Metab Syndr. 2023;15(1):18. doi: 10.1186/s13098-023-00989-z
  19. Castro RE, Ferreira DM, Afonso MB, et al. miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease. J Hepatol. 2013;58(1):119-125. doi: 10.1016/j.jhep.2012.08.008
  20. Yang W, Liu J, Shan Z, et al. Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial. Lancet Diabetes Endocrinol. 2014;2(1):46-55. doi: 10.1016/S2213-8587(13)70021-4
  21. Bai XP, Li TT, Guo LL, Wang J, Dong F. The Influence of Hyperglycemia on Liver Triglyceride Deposition in Partially Pancreatectomized Rats. Horm Metab Res. 2024;56(2):159-166. doi: 10.1055/a-2198-1132
  22. Subramanian P, Hampe J, Tacke F, Chavakis T. Fibrogenic Pathways olic Dysfunction Associated Fatty Liver Disease (MAFLD). Int J Mol Sci. 2022;23(13):6996. doi: 10.3390/ijms23136996
  23. Sauerbruch T, Hennenberg M, Trebicka J, Beuers U. Bile Acids, Liver Cirrhosis, and Extrahepatic Vascular Dysfunction. Front Physiol. 2021;12:718783. doi: 10.3389/fphys.2021.718783
  24. Nadinskaia M, Maevskaya M, Ivashkin V, et al. Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol. 2021;27(10):959-975. doi: 10.3748/wjg.v27.i10.959
  25. Li H, Wang Q, Chen P, Zhou C, Zhang X, Chen Li. Ursodeoxycholic Acid Treatment Restores Gut Microbiota and Alleviates Liver Inflammation in Non-Alcoholic Steatohepatitic Mouse Model. Front Pharmacol. 2021;12:788558. doi: 10.3389/fphar.2021.788558
  26. Mueller M, Thorell A, Claudel T, et al. Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity. J Hepatol. 2015;62(6):1398-1404. doi: 10.1016/j.jhep.2014.12.034
  27. Matsukawa T, Yagi T, Uchida T, et al. Hepatic FASN deficiency differentially affects nonalcoholic fatty liver disease and diabetes in mouse obesity models. JCI Insight. 2023;8(17):e161282. doi: 10.1172/jci.insight.161282
  28. Chen YS, Liu HM, Lee TY. Ursodeoxycholic Acid Regulates Hepatic Energy Homeostasis and White Adipose Tissue Macrophages Polarization in Leptin-Deficiency Obese Mice. Cells. 2019;8(3):253. doi: 10.3390/cells8030253
  29. Mouzaki M, Wang AY, Bandsma R, et al. Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease. PLoS ONE. 2016;11(5):e0151829. doi: 10.1371/journal.pone.0151829
  30. Allen K, Jaeschke H, Copple BL. Bile acids induce inflammatory genes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis. Am J Pathol. 2011;178(1):175-186. doi: 10.1016/j.ajpath.2010.11.026
  31. Taylor R, Basaly V, Kong B, et al. Effects of therapeutically approved individual bile acids on the development of metabolic dysfunction-associated steatohepatitis a low bile acid mouse model. Toxicol Sci. 2024;202(2):179-195. doi: 10.1093/toxsci/kfae110
  32. Mak KM, Chen LL, Lee TF. Codistribution of collagen type IV and laminin in liver fibrosis of elderly cadavers: immunohistochemical marker of perisinusoidal basement membrane formation. Anat Rec. 2013;296(6):953-964. doi: 10.1002/ar.22694
  33. Liu Y, Zhang J, Chen Y, et al. The correlation and role analysis of COL4A1 and COL4A2 in hepatocarcinogenesis. Aging. 2020;12(1):204-223. doi: 10.18632/aging.102610
  34. Elhini SH, Wahsh EA, Elberry AA, et al. The Impact of an SGLT2 Inhibitor versus Ursodeoxycholic Acid on Liver Steatosis in Diabetic Patients. Pharmaceuticals. 2022;15(12):1516. doi: 10.3390/ph15121516
  35. Chiang JYL, Ferrell JM. Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy. Am J Physiol Gastrointest Liver Physiol. 2020;318(3):G554-573. doi: 10.1152/ajpgi.00223.2019
  36. Brevini T, Maes M, Webb GJ, et al. FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2. Nature. 2023;615(7950):134-142. doi: 10.1038/s41586-022-05594-0
  37. Hatting M, Tavares CDJ, Sharabi K, Rines AK, Puigserver P. Insulin regulation of gluconeogenesis. Ann N Y Acad Sci. 2018;1411(1):21-35. doi: 10.1111/nyas.13435
  38. Renga B, Mencarelli A, D’Amore C, et al. Glucocorticoid receptor mediates the gluconeogenic activity of the farnesoid X receptor in the fasting condition. FASEB J. 2012;26(7):3021-3031. doi: 10.1096/fj.11-195701
  39. Wang XX, Xie C, Libby AE, et al. The role of FXR and TGR5 in reversing and preventing progression of Western diet-induced hepatic steatosis, inflammation, and fibrosis in mice. J Biol Chem. 2022;298(11):102530. doi: 10.1016/j.jbc.2022.102530
  40. Pathak P, Liu H, Boehme S, et al. Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism. J Biol Chem. 2017;292(26):11055-11069. doi: 10.1074/jbc.M117.784322
  41. Spatz M, Ciocan D, Merlen G, et al. Bile acid-receptor TGR5 deficiency worsens liver injury in alcohol-fed mice by inducing intestinal microbiota dysbiosis. JHEP Rep. 2021;3(2):100230. doi: 10.1016/j.jhepr.2021.100230
  42. Yoon S, Lee H, Ji SC, Yoon SH, Cho JY, Chung JY. Pharmacokinetics and Pharmacodynamics of Ursodeoxycholic Acid in an Overweight Population With Abnormal Liver Function. Clin Pharmacol Drug Dev. 2021;10(1):68-77. doi: 10.1002/cpdd.790
Share
Back to top
Journal of Clinical and Translational Research, Electronic ISSN: 2424-810X Print ISSN: 2382-6533, Published by AccScience Publishing
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here
Accept